ACTEMRA® (tocilizumab)
ALECENSA® (alectinib)
Avastin® (bevacizumab)
COTELLIC® (cobimetinib)
ENSPRYNG® (satralizumab-mwge)
Erivedge® (vismodegib)
Esbriet® (pirfenidone)
Evrysdi® (risdiplam)
GAVRETO® (pralsetinib)
GAZYVA® (obinutuzumab)
HEMLIBRA® (emicizumab-kxwh)
Herceptin® (trastuzumab)
Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
KADCYLA® (ado-trastuzumab emtansine)
LUCENTIS® (ranibizumab injection)
LUNSUMIO™ (mosunetuzumab-axgb)
OCREVUS® (ocrelizumab)
PERJETA® (pertuzumab)
PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
POLIVY® (polatuzumab vedotin-piiq)
Pulmozyme® (dornase alfa) Inhalation Solution
Rituxan® (rituximab) for Rheumatoid Arthritis (RA)
RITUXAN® (rituximab) for Oncology
Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA) or Pemphigus Vulgaris (PV)
RITUXAN HYCELA® (rituximab/hyaluronidase human)
ROZLYTREK® (entrectinib)
SUSVIMO™ (ranibizumab injection)
TECENTRIQ® (atezolizumab)
VABYSMO® (faricimab-svoa)
VENCLEXTA® (venetoclax tablets)
XOLAIR® (omalizumab) for subcutaneous use
ZELBORAF® (vemurafenib)
Oncology
Ophthalmology
Rheumatology
Benefits Investigations
OCREVUS Access Solutions can conduct a benefits investigation (BI) to help you determine if a Genentech medicine is covered, if prior authorizations (PAs) are required, which specialty pharmacy (SP) the health insurance plan prefers and if financial assistance might be needed.
Potential outcomes of a BI:
- Treatment is covered
- PA is required
- Treatment is denied
Once the BI is complete, your Patient Navigator will walk your patient through his or her insurance coverage for OCREVUS.
A BI may be initiated once the OCREVUS Start Form is submitted to OCREVUS Access Solutions.
This form can be downloaded from Forms and Documents, submitted online via My Patient Solutions.
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
Prior Authorization
Your OCREVUS Patient Navigator can help you identify if a prior authorization (PA) is necessary and offer resources as you obtain it for your patient. Once your practice has submitted a PA, your Patient Navigator can follow up with the payer regarding the PA status. Remember, submitting the PA is the responsibility of the practice. PA support may be provided once the OCREVUS Start Form is submitted to OCREVUS Access Solutions..
If your patient’s request for a PA is not granted, your Clinical and Reimbursement Manager (CRM) or Patient Navigator can work with you to determine your next steps. You can find more tips like this in Forms and Documents.
The completion and submission of coverage- or reimbursement-related documentation are the responsibility of the patient and health care provider. Genentech makes no representation or guarantee concerning coverage or reimbursement for any service or item.
Benefits Reverification
Your OCREVUS Patient Navigator can help you prepare for subsequent OCREVUS treatments by automatically reverifying your patient’s benefits prior to the next scheduled infusion.
For assistance, call (877) GENENTECH/(877) 436-3683
6 a.m.–5 p.m. PT, Monday through Friday
Patient Assistance Tool
Find the right assistance option for your patients